Hemostemix is an
autologous stem cell therapy company, founded in 2003. A winner of the World
Economic Forum Technology Pioneer Award, the Company has developed, patented,
and is scaling a patient’s blood-based stem cell therapeutics platform that
includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte
cell precursors. The proprietary platform technology is backed by more than 10
years of clinical data demonstrating the ability of autologous stem cells to
regenerate diseased and damaged tissue. This platform has the potential to
generate therapies for a broad range of ischemic diseases including critical
limb ischemia, and ischemic heart disease. Under compassionate use exemption,
their lead candidate, ACP-01 has been used to treat Critical Limb Ischemia in
16 patients, with no deaths and the limbs saved on 12 of those patients.


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.